We recently compiled a list of the 15 Stocks That Will Go to The Moon According to Analysts. In this article, we are going to ...

NICE has upheld its decision not to recommend Alzheimer's treatments donanemab and lecanemab for NHS use, citing high costs ...

In a report released yesterday, William Pickering from Bernstein maintained a Hold rating on Biogen (BIIB – Research Report), with a price ...

Shareholders of Biogen would probably like to forget the past six months even happened. The stock dropped 31.4% and now ...

Jones Financial Companies Lllp boosted its holdings in Biogen Inc. (NASDAQ:BIIB – Free Report) by 37.2% in the 4th quarter, ...

In a report released today, David Amsellem from Piper Sandler maintained a Hold rating on Biogen (BIIB – Research Report), with a price target ...

Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results tomorrow morning. Here’s what to look for. Biogen beat analysts’ revenue expectations by 1.2% last quarter, reporting ...

Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the April 25th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB options ...

High-rolling investors have positioned themselves bullish on Biogen BIIB, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of ...

Under the terms of the deal, Bedford, Mass.-based Stoke STOK will retain exclusive rights for the treatment called zorevunersen in the U.S., Canada and Mexico, while Cambridge, Mass.-based Biogen BIIB ...

In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the other stocks. While stocks initially fell based on worries regarding Trump tariffs on America’s ...